Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04954274
Other study ID # P170706J
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date July 29, 2021
Est. completion date July 29, 2026

Study information

Verified date April 2024
Source Assistance Publique - Hôpitaux de Paris
Contact Jean Philippe Mr WOLF, MD-PhD
Phone 01 58 41 37 31
Email jean-philippe.wolf@aphp.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Demonstrate the improvement of the live births rate after ICSI by supplementing the pre-ICSI incubation medium of oocytes and that of preimplantation embryos with cpFT at the 1st embryo transfer for women under 37 years old.


Description:

Supplementation of the incubation medium with cFEE should improve the implantation rate and ART outcome. As in France ICSI is widely used to achieve good fertilization rates, we decided to use ICSI to fertilize the egg, and the peptide: 1. to improve chromosome segregation during meiosis, and 2. to improve in vitro embryogenesis after ICSI. Hence the protocol includes an oocyte preincubation step prior to ICSI and a co incubation of the embryo with the molecule during blastocyst formation. Hence our protocol includes: 1. - a preincubation of the decoronized oocytes with the peptide prior to ICSI, and 2. - a coincubation of the developing embryo with the molecule. The principal criteria will be the live baby rate after the first embryo transfer (using the best embryo). As the oocyte loses its strength as the women is getting older, the main criteria will be evaluated for women under 37 years old. Randomization: every couple will be randomly assigned to the Control or the Treated group. Treated group: After egg retrieval, the oocyte will be decoronized and incubated prior to ICSI procedure into CSCM-C (Irvine) medium supplemented with the molecule. Control group: similar protocol of incubation but without the molecule. After ICSI the zygote will be incubated until the blastocyste stage in CSCM-C medium (Irvine). Embryo transfer will be limited to only one blastocyst, fresh or delayed after cryopreservation.


Recruitment information / eligibility

Status Recruiting
Enrollment 366
Est. completion date July 29, 2026
Est. primary completion date July 29, 2025
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 36 Years
Eligibility Inclusion Criteria: - Couples eligible for a first attempt at Assisted Reproduction (AMP). - Couples asking for Assisted Reproductive Technology, and requiring an ICS procedure. - Women aged 18 to 36 inclusive. - Men aged 18 to 58 inclusive - Use of CSCM-C culture medium from Biocare / Irvine, exclusively. - People affiliated to a Social Security scheme Exclusion Criteria: - Lack of consent - Early menopause. - Couples under IVF or Intra Uterine Insemination treatment. - Patients resumed after a first attempt by the couple. - People unable to follow protocol visits in France. - Couple with a contraindication to treatment with ART. - Women with a contraindication to treatment with ART or an associated pathology such as: hypertension, risk of eclampsia, viral risk, family genetic problems, diabetes, uterine partitions, synechiae adhesions, adenomyosis or any other contraindication judged as such by the investigator. - AMP with donation of gametes or embryos. - Frozen sperm. - Participant under guardianship or guardianship

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Cyclic peptide Fertiline
Upon retrieval, the oocyte will be decoronized and incubated prior to ICSI procedure into CSCC-M medium supplemented with the molecule. After ICSI, the zygote will be incubated in CSCM-C medium supplemented with the peptide.

Locations

Country Name City State
France Department Biology of Reproduction, Hospital Cochin AP-HP Paris

Sponsors (1)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

References & Publications (2)

Barraud-Lange V, Naud-Barriant N, Ducot B, Chambris S, Bomsel M, Wolf JP, Ziyyat A. Cyclic QDE peptide increases fertilization rates and provides healthy pups in mouse. Fertil Steril. 2009 May;91(5 Suppl):2110-5. doi: 10.1016/j.fertnstert.2008.05.088. Epub 2008 Aug 9. — View Citation

Ziyyat A, Naud-Barriant N, Barraud-Lange V, Chevalier F, Kulski O, Lemkecher T, Bomsel M, Wolf JP. Cyclic FEE peptide increases human gamete fusion and potentiates its RGD-induced inhibition. Hum Reprod. 2005 Dec;20(12):3452-8. doi: 10.1093/humrep/dei241. Epub 2005 Aug 11. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Live birth rate after the first embryo transfer Demonstration of the improvement in the rate of live births after ICSI by supplementing the pre-ICSI incubation medium of oocytes and that of preimplantation embryos with cpFT (1µM) during the 1st embryo transfer in women under 37 years of age. 28 months after the first inclusion
Secondary Level of Metaphase II oocytes Through study completion average 16 months
Secondary Quality of the embryonic culture The measure evaluates the rate and number of fertilized eggs over the total number of metaphase 2 oocytes. 16 months after the first inclusion
Secondary Evaluation of the kinetics of embryonic development when possible. The embryos will be kept in an incubator with an embryoscope so that their cleavage sequences will be registered "when possible". The criteria will analysis the cleavage sequences of all embryos during preimplantation embryogenesis. 16 months after the first inclusion
Secondary Embryonic quality at the blastocyst stage All the embryos that will reach the blastocyst stage will be evaluated according to the Gardner criteria. Day 5-6 after ICSI
Secondary Quality of the embryos after vitrification The percentage of Good and Top embryos after thawing will be compared to the grading for the same embryo before cryopreservation according to Gardner criteria Day 5-6 after ICSI
Secondary Implantation rate with positive Beta hCG after transfer 20 months after the first inclusion
Secondary Clinical pregnancy rates with cardiac activity 22 months after the first inclusion
Secondary The rate of miscarriages per pregnancy 22 months after the first inclusion
Secondary rate of abnormality on morphological ultrasounds It reports the percentage of morphological ultrasounds showing an abnormality in the fetus morphology on the total number of morphological ultrasounds performed for all the pregnancies depending of the study. 28 months after the beginning of the study
Secondary rate of neonatal abnormality It reports the percentage of neonatal baby examination showing an abnormality over the total number of neonatal baby examination performed for all the babies who will born during the study. 28 months after the beginning of the study
Secondary children's development It reports the percentage of one year old baby examinations showing an abnormality over the total number of one year old baby examinations performed for all the babies who will born during the study. 45 months after the beginning of the study
See also
  Status Clinical Trial Phase
Completed NCT03607409 - Role of Inhibin A as Biomarker for Ovarian Response for IVF Treatment
Recruiting NCT02312076 - GnRHa for Luteal Phase Support in Long GnRHa Protocol Cycles Phase 4
Terminated NCT02161861 - Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study N/A
Completed NCT03287479 - Comparison of a Semi-automated Closed Vitrification System (Gavi®) With a Manual Open Vitrification Sytem (Cryotop®) N/A
Terminated NCT03522350 - Randomized Trial Comparing EmbryoScope With EmbryoScope+. N/A
Completed NCT04496284 - Embryo Transfer Outcomes After Vitrification With Slush Nitrogen Compared to Liquid Nitrogen N/A
Completed NCT03623659 - pArtiaL zonA pelluciDa Removal by assisteD hatchINg of Blastocysts N/A
Completed NCT03895099 - New Ovarian Stimulation With Random Start, Use of Progestin Protocol for Oocyte Donors Phase 3
Active, not recruiting NCT04142112 - Randomized, Standard-Controlled, Study to Evaluate the Ohana IVF Sperm Preparation Kit, SPeRtility IVF Next Generation N/A
Completed NCT03152643 - Cumulative Live Birth Rates After Cleavage-stage Versus Blastocyst-stage Embryo Transfer N/A
Recruiting NCT03683771 - Assessment of Endometrial Pattern and Sub-endometrial Vascularity in ICSI Outcome
Recruiting NCT03161119 - Comparing Two Different Embryo Transfer Catheters N/A
Completed NCT04108039 - Micronized Progesterone vs Gonadotropin-releasing Hormone (GnRH) Antagonist in Freeze-all IVF Cycles. N/A
Completed NCT03678558 - Oocyte Vitrification Aided With Cytochalasin B N/A
Completed NCT03678597 - Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin B ( ICSI-LB) N/A
Completed NCT03678584 - Supplementing Intracytoplasmic Sperm Injection Handling Medium With Chaetoglobosin A ( ICSI-CA) N/A
Completed NCT03677492 - Supplementing Intracytoplasmic Sperm Injection Handling Medium With Cytochalasin D ( ICSI-CD) N/A
Completed NCT03678571 - Oocyte Vitrification Aided With Latrunculin A N/A
Completed NCT03678818 - Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin A (ICSI-LA) N/A
Completed NCT03678610 - Handling Medium for ICSI With Ionomycin and Latrunculin A N/A